Bruce D. Trapp

Bruce D. Trapp

Auto-generated profile, based on publicly available information

Bruce D. Trapp

Department of Neurosciences, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Annual Review of Neuroscience
Verified
Journal Article
Closed access
BTBruce D. Trapp
Bruce D. Trapp
KNKlaus-Armin Nave
Klaus-Armin Nave
Multiple sclerosis (MS) is an inflammatory-mediated demyelinating disease of the human central nervous system. The clinical disease course is variable, usually starts with reversible episodes of neurological disability in the third or fourth decade of life, and transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade. We review data that support neurodegeneration as the major cause of irreversible neurological disability in MS patients. We question whether inflammatory demyelination is primary or secondary in the disease process and discuss the challenges of elucidating the cause of MS and developing therapies that will delay or prevent the irreversible and progressive neurological decline that most MS patients endure.

31 August 2001 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JPJohn W. Peterson
John W. Peterson
LBLars Bö
Lars Bö
SMSverre Mörk
Sverre Mörk
ACAnsi Chang
Ansi Chang
BTBruce D. Trapp
Bruce D. Trapp

17 January 2002 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
ACAnsi Chang
Ansi Chang
WTWallace W. Tourtellotte
Wallace W. Tourtellotte
RRRichard Rudick
Richard Rudick
BTBruce D. Trapp
Bruce D. Trapp
Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination.

17 February 2006 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RDRanjan Dutta
Ranjan Dutta
JMJennifer McDonough
Jennifer McDonough
XYXinghua Yin
Xinghua Yin
JPJohn Peterson
John Peterson
ACAnsi Chang
Ansi Chang
BTBruce D. Trapp
Bruce D. Trapp

1 September 2000 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ACAnsi Chang
Ansi Chang
ANAkiko Nishiyama
Akiko Nishiyama
JPJohn Peterson
John Peterson
JPJohn Prineas
John Prineas
BTBruce D. Trapp
Bruce D. Trapp
Multiple sclerosis (MS) is characterized by multifocal loss of myelin, oligodendrocytes, and axons. Potential MS therapies include enhancement of remyelination by transplantation or manipulation of endogenous oligodendrocyte progenitor cells. Characteristics of endogenous oligodendrocyte progenitors in normal human brain and in MS lesions have not been studied extensively. This report describes the distribution of cells in sections from normal adult human brain and MS lesions by using antibodies directed against NG2, an integral membrane chondroitin sulfate proteoglycan expressed by oligodendrocyte progenitor cells. Stellate-shaped NG2-positive cells were detected in the white and gray matter of normal adult human brain and appeared as abundant as, but distinct from, astrocytes, oligodendrocytes, and microglia. Stellate-shaped or elongated NG2-positive cells also were detected in chronic MS lesions. A subpopulation of the elongated NG2-positive cells expressed the putative apoptotic signaling molecule p75NTR. TUNEL-positive cells in three active, nine chronic active, and four chronic inactive lesions, however, were p75NTR-negative. These studies identify cells with phenotypic markers of endogenous oligodendrocyte progenitors in the mature human CNS and suggest that functional subpopulations of NG2-positive cells exist in MS lesions. Endogenous oligodendrocyte progenitor cells may represent a viable target for future therapies intended to enhance remyelination in MS patients.

1 March 2009 in The Lancet Neurology
Verified
Journal Article
Closed access
BTBruce D Trapp
Bruce D Trapp
PSPeter K Stys
Peter K Stys